1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €1.29 (-85.55%). The median is €1.29 (-85.55%).
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | May 2026 | |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | 0 | 100.00% |
| Net profit | -1.71M | 48.81% |
| EBITDA | -1.71M | 48.36% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €16.66M |
Number of shares | 1.65M |
52-week high/low | €20.07 - €3.63 |
| Dividends | No |
Beta | 0.34 |
P/E ratio | -2.20 |
PEG ratio | -0.03 |
P/B ratio | 4.08 |
P/S ratio | 99.49 |
Company profile
| Name | Lexaria Bioscience Corp |
| CEO | Richard C. Christopher |
| Employees | 7 |
Discover assets
Shareholders of Lexaria Bioscience Corp also invest in the following assets
